BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34946865)

  • 1. BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report.
    Pepe F; Pisapia P; Russo G; Nacchio M; Pallante P; Vigliar E; De Angelis C; Insabato L; Bellevicine C; De Placido S; Troncone G; Malapelle U
    Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
    Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
    Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M
    Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
    BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
    Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
    Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
    Wallbillich JJ; Morris RT; Ali-Fehmi R
    Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing.
    Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
    Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
    Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
    McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
    Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion
    Vidula N; Rich TA; Sartor O; Yen J; Hardin A; Nance T; Lilly MB; Nezami MA; Patel SP; Carneiro BA; Fan AC; Brufsky AM; Parker BA; Bridges BB; Agarwal N; Maughan BL; Raymond VM; Fairclough SR; Lanman RB; Bardia A; Cristofanilli M
    Clin Cancer Res; 2020 Jun; 26(11):2546-2555. PubMed ID: 32034076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
    Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of BRCA testing on cytologic samples of high-grade serous carcinoma.
    Lou SK; Grenier S; Care M; McCuaig J; Stockley TL; Clarke B; Ruff HM; Boerner SL
    Cancer Cytopathol; 2021 Nov; 129(11):907-913. PubMed ID: 34157791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
    Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequencing of
    Ebner S; Winkelmann R; Martin S; Köllermann J; Wild PJ; Demes M
    Oncotarget; 2022; 13():464-475. PubMed ID: 35251494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.